A STUDY OF ROACTEMRA/ACTEMRA (TOCILIZUMAB) IN MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE OR OTHER NON-BIOLOGIC DMARDS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CURRENT NON-BIOLOGIC DMARD THERAPY OR THE FIRST ANTI-TNF BIOLOGIC AGENT: